GLP-1 Generics: The Weight-Loss Revolution
The most anticipated development of 2026 is the emergence of generic GLP-1 receptor agonists (semaglutide and liraglutide). These drugs, used for Type 2 diabetes and chronic weight management, have faced global shortages and high costs (often exceeding $900–$1,300 per month without insurance).
First-to-File Rights: In early 2026, companies like Mylan and Natco Pharma are poised to launch the first generic versions of semaglutide following landmark legal settlements.
Market Expansion: Experts predict that the introduction of generics will not only lower prices but also stabilize the global supply chain, which has struggled to meet the "tidal wave" of demand for anti-obesity medications since 2023.